Oncology catalog

Lynza 150mg Tablet contains olaparib, a targeted anticancer agent belonging to the class of poly (ADP-ribose) polymerase (PARP) inhibitors. It is used in the treatment and maintenance therapy of ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer, particularly in patients with specific genetic mutations such as BRCA mutations. PARP enzymes help cancer cells repair damaged DNA, and by blocking PARP activity, olaparib causes DNA damage to accumulate in cancer cells, leading to their death and slowing tumour growth. Lynza 150mg Tablet is taken orally, with or without food, under specialist supervision as part of a comprehensive cancer management plan.